ARTICLE | Regulation
FDA performance
December 10, 2001 8:00 AM UTC
Priority and standard median approval times for new molecular entities in calendar years 1995-2000. Total approval time reflects the aggregate time that has elapsed between filing of a BLA or NDA an...